Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 35,530	$ 59,074
Accounts receivable	3,137	23
Inventory	5,124
Deferred costs from collaboration		13,539
Deferred costs from commercial product sales	279
Prepaid expenses and other current assets	4,534	4,018
Total current assets	48,604	76,654
Property and equipment - net	46,825	48,749
Other assets	702	1,009
Total assets	96,131	126,412
Current liabilities:
Accounts payable	5,093	15,599
Accrued expenses and other current liabilities	14,164	7,929
Facility financing obligation	70,888	74,582
Deferred sales from collaboration		17,503
Deferred payments from collaboration	462	140,231
Deferred revenue	2,014
Recognized loss on purchase commitments - current	8,340	12,475
Warrant liability	4,871
Total current liabilities	105,832	268,319
Note payable to our principal stockholder	49,521	49,521
Sanofi loan facility and loss share obligation	71,210	62,371
Senior convertible notes - long term	27,629	27,613
Recognized loss on purchase commitments - long term	63,229	53,692
Other liabilities	17,397	15,225
Total liabilities	334,818	476,741
Commitments and contingencies
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2016 and December 31, 2015
Common stock, $0.01 par value - 700,000,000 and 550,000,000 shares authorized at September 30, 2016 and December 31, 2015, respectively; 478,362,548 and 428,670,943 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively	4,784	4,287
Additional paid-in capital	2,548,090	2,508,633
Accumulated other comprehensive loss	(21)	(20)
Accumulated deficit	(2,791,540)	(2,863,229)
Total stockholders' deficit	(238,687)	(350,329)
Total liabilities and stockholders' deficit	$ 96,131	$ 126,412